Lupin re-introduces Methergine tablets

BALTIMORE — Lupin on Thursday announced that it would be re-introducing its Methergine (methylergonovine maleate) tablets. The drug is indicated to manage uterine atony, hemorrhage and subinvolution of the uterus following delivery of the placenta, and for control of uterine hemorrhage in the second stage of labor. It's also the preferred treatment for postpartum hemorrhage, according to American Congress of Obstetricians and Gynecologists (ACOG) guidelines. 

 

“The re-introduction of Methergine is a proud moment for Lupin, but also an important moment for expectant mothers across the country to feel confident in care options,” Lupin Pharmaceuticals president Paul McGarty said. “With Methergine, Lupin is making a significant investment to help improve the management of PPH, providing professional medical education, leveraging its specialized sales force to drive better awareness and access to care, and ensuring a more stable supply of this essential medicine.” 

 

Lupin noted that one area where education is needed is in discerning accurate blood loss, which can be a barrier to optimal care. Underestimating blood loss can delay interventions and over-estimating can lead to such costly, unnecessary treatments as blood transfusions. 

 

“Postpartum hemorrhage (PPH) is one of the most preventable causes of maternal mortality and it should be better managed in pursuit of improved patient care,” said Dr. David Schwartz, OBGYN and American Congress of Obstetricians and Gynecologists fellow, said. “I commend Lupin for spotlighting this public health issue and making an investment in treatment, education and awareness of PPH.”